Transcriptome Sequencing of Tumor Subpopulations Reveals a Spectrum of Therapeutic Options for Squamous Cell Lung Cancer

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Barrett, Christian L ^a,b   Schwab, Richard B ^a,c   Jung, HyunChul ^a,c   Crain, Brian ^a   Goff, Daniel J ^d   Jamieson, Catriona H M ^d   Thistlethwaite, Patricia A ^c   Harismendy, Olivier ^a,b,c   Carson, Dennis A ^e   Frazer, Kelly A ^a,b,c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b RADY CHILDREN'S HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e SANFORD CONSORTIUM FOR REGENERATIVE MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; ADAM10 ENDOPEPTIDASE; BREAST CANCER RESISTANCE PROTEIN; CD133 ANTIGEN; CD151 ANTIGEN; CD47 ANTIGEN; CELL SURFACE PROTEIN; CHEMOKINE RECEPTOR CXCR4; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; FLICE INHIBITORY PROTEIN; HERMES ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; MYC PROTEIN; PROTEIN BCL XL; PROTEIN MCL 1; TRANSCRIPTOME; TRANSIENT RECEPTOR POTENTIAL CHANNEL M7; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL; CELL ISOLATION; CELL SELECTION; CELL SUBPOPULATION; CONTROLLED STUDY; DNA SEQUENCE; FLUORESCENCE ACTIVATED CELL SORTING; GENE DOSAGE; GENOTYPE; HUMAN; HUMAN CELL; LUNG CANCER; NONHUMAN; PROTEIN EXPRESSION; RNA SEQUENCE; SQUAMOUS CELL CARCINOMA;

ANIMALS; ANTIGENS, CD; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; DNA COPY NUMBER VARIATIONS; DNA, NEOPLASM; GLYCOPROTEINS; HUMANS; LUNG NEOPLASMS; MEMBRANE PROTEINS; MICE; MUTATION; NEOPLASTIC STEM CELLS; PEPTIDES; RNA, MESSENGER; RNA, NEOPLASM; TRANSCRIPTOME; TRANSPLANTATION, HETEROLOGOUS;

EID: 84875130587     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058714     Document Type: Article

References (96)

1. Siegel R, Ward E, Brawley O, Jemal A, (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA 61: 212-236 doi:10.3322/caac.20121.
2. Heukamp LC, Wolf J, Büttner R, (2011) Molecular diagnostics of lung cancer for treatment stratification. Der Internist 52: 146, 148-150, 152-154 doi:10.1007/s00108-010-2698-y.
3. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, et al. (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22: 2184-2191 doi:10.1200/JCO.2004.11.022.
4. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, et al. (2006) Paclitaxel-Carboplatin Alone or with Bevacizumab for Non-Small-Cell Lung Cancer. N Engl J Med 355: 2542-2550.
5. Langer CJ, Besse B, Gualberto A, Brambilla E, Soria J-C, (2010) The evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol 28: 5311-5320 doi:10.1200/JCO.2010.28.8126.
6. Weiss J, Sos ML, Seidel D, Peifer M, Zander T, et al. (2010) Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2: 62ra93 doi:10.1126/scitranslmed.3001451.
7. Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, et al. (2011) Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer. Cancer Discov 1: 78-89 doi:10.1158/2159-8274.CD-11-0005.
8. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, et al. (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455: 1069-1075 doi:10.1038/nature07423.
9. Weir BA, Woo MS, Getz G, Perner S, Ding L, et al. (2007) Characterizing the cancer genome in lung adenocarcinoma. Nature 450: 893-898 doi:10.1038/nature06358.
10. Bell D, Berchuck A, Birrer M, Chien J, Cramer DW, et al. (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615 doi:10.1038/nature10166.
11. Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, et al. (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98-110 doi:10.1016/j.ccr.2009.12.020.
12. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, et al. (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455: 1069-1075 doi:10.1038/nature07423.
13. The Cancer Genome Atlas website. Available: http://cancergenome.nih.gov.
14. Clevers H, (2011) The cancer stem cell: premises, promises and challenges. Nature Med 17: 313-319 doi:10.1038/nm.2304.
15. Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, et al. (2009) Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA 106: 16281-16286 doi:10.1073/pnas.0905653106.
16. Perona R, López-Ayllón BD, Castro Carpeño J, Belda-Iniesta C, (2011) A role for cancer stem cells in drug resistance and metastasis in non-small-cell lung cancer. Clin Transl Oncol 13: 289-293 doi:10.1007/s12094-011-0656-3.
17. Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, et al. (2011) Stochastic State Transitions Give Rise to Phenotypic Equilibrium in Populations of Cancer Cells. Cell 146: 633-644 doi:10.1016/j.cell.2011.07.026.
18. Quintana E, Shackleton M, Foster HR, Fullen DR, Sabel MS, et al. (2010) Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 18: 510-523 doi:10.1016/j.ccr.2010.10.012.
19. Sultan M, Schulz MH, Richard H, Magen A, Klingenhoff A, et al. (2008) A global view of gene activity and alternative splicing by deep sequencing of the human transcriptome. Science 321: 956-960 doi:10.1126/science.1160342.
20. Skotheim RI, Nees M, (2007) Alternative splicing in cancer: noise, functional, or systematic? Int J Biochem Cell Biol 39: 1432-1449 doi:10.1016/j.biocel.2007.02.016.
21. He X, Ee PLR, Coon JS, Beck WT, (2004) Alternative splicing of the multidrug resistance protein 1/ATP binding cassette transporter subfamily gene in ovarian cancer creates functional splice variants and is associated with increased expression of the splicing factors PTB and SRp20. Clin Cancer Res 10: 4652-4660 doi:10.1158/1078-0432.CCR-03-0439.
22. Parajes M, Ezponda M, Catena R, Calvo A, Pio R, et al. (2007) Alternative splicing: an emerging topic in molecular and clinical oncology. Lancet Oncol 8: 349-357 doi:10.1016/S1470-2045(07)70104-3.
23. Grosso AR, Martins S, Carmo-Fonseca M, (2008) The emerging role of splicing factors in cancer. EMBO Reports 9: 1087-1093 doi:10.1038/embor.2008.189.
24. Venables JP, (2006) Unbalanced alternative splicing and its significance in cancer. BioEssays 28: 378-386 doi:10.1002/bies.20390.
25. Tirino V, Camerlingo R, Franco R, Malanga D, La Rocca A, et al. (2009) The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. Eur J Cardio-thoracic Surgery 36: 446-453 doi:10.1016/j.ejcts.2009.03.063.
26. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, et al. (2008) Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 15: 504-514 doi:10.1038/sj.cdd.4402283.
27. Chen Y-C, Hsu H-S, Chen Y-W, Tsai T-H, How C-K, et al. (2008) Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PloS ONE 3: e2637 doi:10.1371/journal.pone.0002637.
28. Hammerman PS, Hayes DN, Wilkerson MD, Schultz N, Bose R, et al. (2012) Comprehensive genomic characterization of squamous cell lung cancers. Nature 489: 519-525 doi:10.1038/nature11404.
29. Homer N, Merriman B, Nelson SF, (2009) BFAST: an alignment tool for large scale genome resequencing. PloS ONE 4: e7767 doi:10.1371/journal.pone.0007767.
30. Pruitt KD, Tatusova T, Maglott DR, (2007) NCBI reference sequences (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins. Nucleic Acids Res 35: D61-5 doi:10.1093/nar/gkl842.
31. Hsu F, Kent WJ, Clawson H, Kuhn RM, Diekhans M, et al. (2006) The UCSC Known Genes. Bioinformatics 22: 1036-1046 doi:10.1093/bioinformatics/btl048.
32. Hubbard T, (2002) The Ensembl genome database project. Nucleic Acids Res 30: 38-41 doi:10.1093/nar/30.1.38.
33. Hebenstreit D, Fang M, Gu M, Charoensawan V, Van Oudenaarden A, et al. (2011) RNA sequencing reveals two major classes of gene expression levels in metazoan cells. Mol Systems Biol 7: 497 doi:10.1038/msb.2011.28.
34. Pinto D, Darvishi K, Shi X, Rajan D, Rigler D, et al. (2011) Comprehensive assessment of array-based platforms and calling algorithms for detection of copy number variants. Nat Biotechnol 29: 512-520 doi:10.1038/nbt.1852.
35. Human Cell Differentiation Molecules Organization website. Available: http://www.hcdm.org.
36. The International Union of Basic and Clinical Pharmacology website. Available: http://www.iuphar.org.
37. Tiwari AK, Sodani K, Wang S-R, Kuang Y-H, Ashby CR, et al. (2009) Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharm 78: 153-161 doi:10.1016/j.bcp.2009.04.002.
38. Moss ML, Stoeck A, Yan W, Dempsey PJ, (2008) ADAM10 as a Target for Anti-Cancer Therapy. Curr Pharm Biotechnol 9: 7.
39. Roth A, Drummond DC, Conrad F, Hayes ME, Kirpotin DB, et al. (2007) Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells. Mol Cancer Ther 6: 2737-2746 doi:10.1158/1535-7163.MCT-07-0140.
40. Wiiger MT, Gehrken HB, Fodstad Ø, Maelandsmo GM, Andersson Y, (2010) A novel human recombinant single-chain antibody targeting CD166/ALCAM inhibits cancer cell invasion in vitro and in vivo tumour growth. Cancer Immunol Immunother 59: 1665-1674 doi:10.1007/s00262-010-0892-3.
41. Kanekura T, Chen X, (2010) CD147/basigin promotes progression of malignant melanoma and other cancers. J Dermatol Sci 57: 149-154 doi:10.1016/j.jdermsci.2009.12.008.
42. Yang XH, Flores LM, Li Q, Zhou P, Xu F, et al. (2010) Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists. Cancer Res 70: 2256-2263 doi:10.1158/0008-5472.CAN-09-4032.
43. Pham PV, Phan NLC, Nguyen NT, Truong NH, Duong TT, et al. (2011) Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy. J Transl Med 9: 209 doi:10.1186/1479-5876-9-209.
44. Uluçkan O, Becker SN, Deng H, Zou W, Prior JL, et al. (2009) CD47 regulates bone mass and tumor metastasis to bone. Cancer Res 69: 3196-3204 doi:10.1158/0008-5472.CAN-08-3358.
45. Chao MP, Weissman IL, Majeti R, (2012) The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications. Curr Opin Immunol 24: 225-232 doi:10.1016/j.coi.2012.01.010.
46. Hwang JR, Jo K, Lee Y, Sung B-J, Park YW, et al. (2012) Upregulation of CD9 in ovarian cancer is related to the induction of TNF-α gene expression and constitutive NF-κB activation. Carcinogenesis 33: 77-83 doi:10.1093/carcin/bgr257.
47. Ovalle S, Gutiérrez-López MD, Olmo N, Turnay J, Lizarbe MA, et al. (2007) The tetraspanin CD9 inhibits the proliferation and tumorigenicity of human colon carcinoma cells. Int J Cancer 121: 2140-2152 doi:10.1002/ijc.22902.
48. Nakamoto T, Murayama Y, Oritani K, Boucheix C, Rubinstein E, et al. (2009) A novel therapeutic strategy with anti-CD9 antibody in gastric cancers. J Gastroenterol 44: 889-896 doi:10.1007/s00535-009-0081-3.
49. Murayama Y, Miyagawa J, Oritani K, Yoshida H, Yamamoto K, et al. (2004) CD9-mediated activation of the p46 Shc isoform leads to apoptosis in cancer cells. J Cell Sci 117: 3379-3388 doi:10.1242/jcs.01201.
50. Kohmo S, Kijima T, Otani Y, Mori M, Minami T, et al. (2010) Cell surface tetraspanin CD9 mediates chemoresistance in small cell lung cancer. Cancer Res 70: 8025-8035 doi:10.1158/0008-5472.CAN-10-0996.
51. Govindan SV, Cardillo TM, Moon S-J, Hansen HJ, Goldenberg DM, (2009) CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates. Clin Cancer Res 15: 6052-6061 doi:10.1158/1078-0432.CCR-09-0586.
52. Blumenthal RD, Hansen HJ, Goldenberg DM, (2005) Inhibition of adhesion, invasion, and metastasis by antibodies targeting CEACAM6 (NCA-90) and CEACAM5 (Carcinoembryonic Antigen). Cancer Res 65: 8809-8817 doi:10.1158/0008-5472.CAN-05-0420.
53. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, et al. (2007) Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1: 313-323 doi:10.1016/j.stem.2007.06.002.
54. Linke R, Klein A, Seimetz D, (2010) Catumaxomab: clinical development and future directions. mAbs 2: 129-136.
55. Yamazaki M, Yamashita Y, Kubo N, Yashiro M, Ohira M, et al. (2012) Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab. Oncol Rep 28: 49.
56. DiPaola RS, Plante M, Kaufman H, Petrylak DP, Israeli R, et al. (2006) A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J Trans Med 4: 1 doi:10.1186/1479-5876-4-1.
57. Fagan DH, Uselman RR, Sachdev D, Yee D, (2012) Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor (IGF1R): implications for breast cancer treatment. Cancer Res To Appear doi:10.1158/0008-5472.CAN-12-0684.
58. Ueyama H, Horibe T, Nakajima O, Ohara K, Kohno M, et al. (2011) Semaphorin 3A lytic hybrid peptide binding to neuropilin-1 as a novel anti-cancer agent in pancreatic cancer. Biochem Biophysical Res Comm 414: 60-66 doi:10.1016/j.bbrc.2011.09.021.
59. Zhang B, (2010) CD73: a novel target for cancer immunotherapy. Cancer Res 70: 6407-6411 doi:10.1158/0008-5472.CAN-10-1544.
60. Zierler S, Yao G, Zhang Z, Kuo WC, Pörzgen P, et al. (2011) Waixenicin A inhibits cell proliferation through magnesium-dependent block of transient receptor potential melastatin 7 (TRPM7) channels. J Biol Chem 286: 39328-39335 doi:10.1074/jbc.M111.264341.
61. Ward Y, Lake R, Yin JJ, Heger CD, Raffeld M, et al. (2011) LPA receptor heterodimerizes with CD97 to amplify LPA-initiated RHO-dependent signaling and invasion in prostate cancer cells. Cancer Res 71: 7301-7311 doi:10.1158/0008-5472.CAN-11-2381.
62. Yu F, Ng SSM, Chow BKC, Sze J, Lu G, et al. (2011) Knockdown of interferon-induced transmembrane protein 1 (IFITM1) inhibits proliferation, migration, and invasion of glioma cells. J Neurooncol 103: 187-195 doi:10.1007/s11060-010-0377-4.
63. Roland CL, Harken AH, Sarr MG, Barnett CC, (2007) ICAM-1 expression determines malignant potential of cancer. Surgery 141: 705-707 doi:10.1016/j.surg.2007.01.016.
64. Kammerer S, Roth RB, Reneland R, Marnellos G, Hoyal CR, et al. (2004) Large-scale association study identifies ICAM gene region as breast and prostate cancer susceptibility locus. Cancer Res 64: 8906-8910 doi:10.1158/0008-5472.CAN-04-1788.
65. The Cancer Genome Atlas website. Available: http://cancergenome.nih.gov.
66. Nakagawa M, Takizawa N, Narita M, Ichisaka T, Yamanaka S, (2010) Promotion of direct reprogramming by transformation-deficient Myc. Proc Natl Acad Sci USA 107: 14152-14157 doi:10.1073/pnas.1009374107.
67. Galbán S, Duckett CS, (2010) XIAP as a ubiquitin ligase in cellular signaling. Cell Death Differ 17: 54-60 doi:10.1038/cdd.2009.81.
68. Sarras H, Alizadeh Azami S, McPherson JP, (2010) In search of a function for BCLAF1. Sci World J 10: 1450-1461 doi:10.1100/tsw.2010.132.
69. McPherson JP, Sarras H, Lemmers B, Tamblyn L, Migon E, et al. (2009) Essential role for Bclaf1 in lung development and immune system function. Cell Death Differ 16: 331-339 doi:10.1038/cdd.2008.167.
70. Zhang H, (2000) BAR: An apoptosis regulator at the intersection of caspases and Bcl-2 family proteins. Proc Natl Acad Sci USA 97: 2597-2602 doi:10.1073/pnas.97.6.2597.
71. Edlich F, Banerjee S, Suzuki M, Cleland MM, Arnoult D, et al. (2011) Bcl-xL Retrotranslocates Bax from the Mitochondria into the Cytosol. Cell 145: 104-116 doi:10.1016/j.cell.2011.02.034.
72. Dunkle A, Dzhagalov I, He Y-W, (2010) Mcl-1 promotes survival of thymocytes by inhibition of Bak in a pathway separate from Bcl-2. Cell Death Differ 17: 994-1002 doi:10.1038/cdd.2009.201.
73. Zhang H, Guttikonda S, Roberts L, Uziel T, Semizarov D, et al. (2011) Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines. Oncogene 30: 1963-1968 doi:10.1038/onc.2010.559.
74. Allen TD, Zhu CQ, Jones KD, Yanagawa N, Tsao M-S, et al. (2011) Interaction between MYC and MCL1 in the genesis and outcome of non-small-cell lung cancer. Cancer Res 71: 2212-2221 doi:10.1158/0008-5472.CAN-10-3590.
75. Meyer N, Penn LZ, (2008) Reflecting on 25 years with MYC. Nat Rev Cancer 8: 976-990 doi:10.1038/nrc2231.
76. Ding W, Yin X (2009) The BCL-2 Family Proteins. In: Dong Z, Yin X-M, editors. Essentials of Apoptosis. Totowa, NJ: Humana Press. doi:10.1007/978-1-60327-381-7.
77. Lacour S, Hammann A, Wotawa A, Corcos L, Solary E, et al. (2001) Anticancer Agents Sensitize Tumor Cells to Tumor Necrosis Factor-related Apoptosis-inducing Ligand-mediated Caspase-8 Activation and Apoptosis. Cancer Res 61: 1645-1651.
78. Malhi H, Gores GJ, (2006) TRAIL resistance results in cancer progression: a TRAIL to perdition? Oncogene 25: 7333-7335 doi:10.1038/sj.onc.1209765.
79. Wang X, Chen W, Zeng W, Bai L, Tesfaigzi Y, et al. (2008) Akt-mediated eminent expression of c-FLIP and Mcl-1 confers acquired resistance to TRAIL-induced cytotoxicity to lung cancer cells. Mol Cancer Ther 7: 1156-1163 doi:10.1158/1535-7163.MCT-07-2183.
80. Taniai M, Grambihler A, Higuchi H, Werneburg N, Bronk SF, et al. (2004) Mcl-1 Mediates Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Resistance in Human Cholangiocarcinoma Cells. Cancer Res 64: 3517-3524 doi:10.1158/0008-5472.CAN-03-2770.
81. Zhu H, Guo W, Zhang L, Davis JJ, Wu S, et al. (2005) Enhancing TRAIL-induced apoptosis by Bcl-X(L) siRNA. Cancer Biol Therapy 4: 393-397.
82. Meng XW, Lee S-H, Dai H, Loegering D, Yu C, et al. (2007) Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. J Biol Chem 282: 29831-29846 doi:10.1074/jbc.M706110200.
83. Kim S-H, Ricci MS, El-Deiry WS, (2008) Mcl-1: a gateway to TRAIL sensitization. Cancer Res 68: 2062-2064 doi:10.1158/0008-5472.CAN-07-6278.
84. Raclaw KA, Heemers HV, Kidd EM, Dehm SM, Tindall DJ, (2008) Induction of FLIP expression by androgens protects prostate cancer cells from TRAIL-mediated apoptosis. The Prostate 68: 1696-1706 doi:10.1002/pros.20844.
85. El-Gazzar A, Wittinger M, Perco P, Anees M, Horvat R, et al. (2010) The role of c-FLIP(L) in ovarian cancer: chaperoning tumor cells from immunosurveillance and increasing their invasive potential. Gynecologic Oncol 117: 451-459 doi:10.1016/j.ygyno.2010.02.024.
86. Haag C, Stadel D, Zhou S, Bachem MG, Möller P, et al. (2011) Identification of c-FLIP(L) and c-FLIP(S) as critical regulators of death receptor-induced apoptosis in pancreatic cancer cells. Gut 60: 225-237 doi:10.1136/gut.2009.202325.
87. Koehler B-C, Urbanik T, Vick B, Boger R-J, Heeger S, et al. (2009) TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies. World J Gastroenterol 15: 5924-5935.
88. Krieg A, Krieg T, Wenzel M, Schmitt M, Ramp U, et al. (2003) TRAIL-beta and TRAIL-gamma: two novel splice variants of the human TNF-related apoptosis-inducing ligand (TRAIL) without apoptotic potential. Br J Cancer 88: 918-927 doi:10.1038/sj.bjc.6600772.
89. Bae J, Leo CP, Hsu SY, Hsueh AJ, (2000) MCL-1S, a splicing variant of the antiapoptotic BCL-2 family member MCL-1, encodes a proapoptotic protein possessing only the BH3 domain. J Biol Chem 275: 25255-25261 doi:10.1074/jbc.M909826199.
90. Yang E, Zha J, Jockel J, Boise LH, Thompson CB, et al. (1995) Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 80: 285-291.
91. Dash R, Azab B, Quinn BA, Shen X, Wang X-Y, et al. (2011) Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity. Proc Natl Acad Sci USA 108: 8785-8790 doi:10.1073/pnas.1100769108.
92. Willis SN, Fletcher JI, Kaufmann T, Van Delft MF, Chen L, et al. (2007) Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 315: 856-859 doi:10.1126/science.1133289.
93. Hyer ML, Croxton R, Krajewska M, Krajewski S, Kress CL, et al. (2005) Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells. Cancer Res 65: 4799-4808 doi:10.1158/0008-5472.CAN-04-3319.
94. Zou W, Chen S, Liu X, Yue P, Sporn MB, et al. (2007) c-FLIP downregulation contributes to apoptosis induction by the novel synthetic triterpenoid methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate (CDDO-Me) in human lung cancer cells. Cancer Biol Therapy 6: 1614-1620.
95. Schultze K, Böck B, Eckert A, Oevermann L, Ramacher D, et al. (2006) Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin. Apoptosis 11: 1503-1512 doi:10.1007/s10495-006-8896-3.
96. Seal RL, Gordon SM, Lush MJ, Wright MW, Bruford EA, (2011) genenames.org: the HGNC resources in 2011. Nucleic Acids Res 39: D514-9 doi:10.1093/nar/gkq892.